The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy

Kyung Jin Eoh, Jung Won Yoon, Inok Lee, Jung Yun Lee, Sunghoon Kim, Sang Wun Kim, YoungTae Kim, Eun Ji Nam

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and Objective: The therapeutic role of systematic lymph node dissection (LND) remains unclear in advanced epithelial ovarian cancer (EOC), especially during interval debulking surgery (IDS) performed after neoadjuvant chemotherapy (NAC). We analyzed the therapeutic and prognostic roles of systematic LND in advanced EOC patients. Methods: Data from consecutive patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV disease, who underwent optimal IDS (<1cm) after NAC, were obtained via a retrospective chart review. Patients were classified into a lymph node sampling (LNS; node count <20) group and an LND (node count ≥20) group. Results: Among 133 study patients, 65 and 68 underwent LND and LNS, respectively, during IDS. Overall survival (OS) was significantly better in the LND group than in the LNS group. In subgroup analysis with negative lymphadenopathy on preoperative imaging, progression-free survival (PFS) and OS were significantly better in the LND group than in the LNS group. Follow-up of subsequent recurrences showed significantly lower nodal and peritoneal recurrence rates among patients who underwent LND. Multivariate analysis identified LND as an independent prognostic factor for PFS and OS. Conclusion: Systematic LND may have therapeutic value in advanced EOC patients treated with NAC and IDS.

Original languageEnglish
Pages (from-to)329-336
Number of pages8
JournalJournal of Surgical Oncology
Volume116
Issue number3
DOIs
Publication statusPublished - 2017 Sep 1

Fingerprint

Lymph Node Excision
Drug Therapy
Disease-Free Survival
Survival
Ovarian epithelial cancer
Recurrence
Gynecology
Obstetrics
Therapeutics
Multivariate Analysis
Lymph Nodes

All Science Journal Classification (ASJC) codes

  • Surgery
  • Oncology

Cite this

Eoh, Kyung Jin ; Yoon, Jung Won ; Lee, Inok ; Lee, Jung Yun ; Kim, Sunghoon ; Kim, Sang Wun ; Kim, YoungTae ; Nam, Eun Ji. / The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy. In: Journal of Surgical Oncology. 2017 ; Vol. 116, No. 3. pp. 329-336.
@article{f3c9b5c5b1b34e01b9d6d0581abee26b,
title = "The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy",
abstract = "Background and Objective: The therapeutic role of systematic lymph node dissection (LND) remains unclear in advanced epithelial ovarian cancer (EOC), especially during interval debulking surgery (IDS) performed after neoadjuvant chemotherapy (NAC). We analyzed the therapeutic and prognostic roles of systematic LND in advanced EOC patients. Methods: Data from consecutive patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV disease, who underwent optimal IDS (<1cm) after NAC, were obtained via a retrospective chart review. Patients were classified into a lymph node sampling (LNS; node count <20) group and an LND (node count ≥20) group. Results: Among 133 study patients, 65 and 68 underwent LND and LNS, respectively, during IDS. Overall survival (OS) was significantly better in the LND group than in the LNS group. In subgroup analysis with negative lymphadenopathy on preoperative imaging, progression-free survival (PFS) and OS were significantly better in the LND group than in the LNS group. Follow-up of subsequent recurrences showed significantly lower nodal and peritoneal recurrence rates among patients who underwent LND. Multivariate analysis identified LND as an independent prognostic factor for PFS and OS. Conclusion: Systematic LND may have therapeutic value in advanced EOC patients treated with NAC and IDS.",
author = "Eoh, {Kyung Jin} and Yoon, {Jung Won} and Inok Lee and Lee, {Jung Yun} and Sunghoon Kim and Kim, {Sang Wun} and YoungTae Kim and Nam, {Eun Ji}",
year = "2017",
month = "9",
day = "1",
doi = "10.1002/jso.24669",
language = "English",
volume = "116",
pages = "329--336",
journal = "Journal of Surgical Oncology",
issn = "0022-4790",
publisher = "Wiley-Liss Inc.",
number = "3",

}

The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy. / Eoh, Kyung Jin; Yoon, Jung Won; Lee, Inok; Lee, Jung Yun; Kim, Sunghoon; Kim, Sang Wun; Kim, YoungTae; Nam, Eun Ji.

In: Journal of Surgical Oncology, Vol. 116, No. 3, 01.09.2017, p. 329-336.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The efficacy of systematic lymph node dissection in advanced epithelial ovarian cancer during interval debulking surgery performed after neoadjuvant chemotherapy

AU - Eoh, Kyung Jin

AU - Yoon, Jung Won

AU - Lee, Inok

AU - Lee, Jung Yun

AU - Kim, Sunghoon

AU - Kim, Sang Wun

AU - Kim, YoungTae

AU - Nam, Eun Ji

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Background and Objective: The therapeutic role of systematic lymph node dissection (LND) remains unclear in advanced epithelial ovarian cancer (EOC), especially during interval debulking surgery (IDS) performed after neoadjuvant chemotherapy (NAC). We analyzed the therapeutic and prognostic roles of systematic LND in advanced EOC patients. Methods: Data from consecutive patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV disease, who underwent optimal IDS (<1cm) after NAC, were obtained via a retrospective chart review. Patients were classified into a lymph node sampling (LNS; node count <20) group and an LND (node count ≥20) group. Results: Among 133 study patients, 65 and 68 underwent LND and LNS, respectively, during IDS. Overall survival (OS) was significantly better in the LND group than in the LNS group. In subgroup analysis with negative lymphadenopathy on preoperative imaging, progression-free survival (PFS) and OS were significantly better in the LND group than in the LNS group. Follow-up of subsequent recurrences showed significantly lower nodal and peritoneal recurrence rates among patients who underwent LND. Multivariate analysis identified LND as an independent prognostic factor for PFS and OS. Conclusion: Systematic LND may have therapeutic value in advanced EOC patients treated with NAC and IDS.

AB - Background and Objective: The therapeutic role of systematic lymph node dissection (LND) remains unclear in advanced epithelial ovarian cancer (EOC), especially during interval debulking surgery (IDS) performed after neoadjuvant chemotherapy (NAC). We analyzed the therapeutic and prognostic roles of systematic LND in advanced EOC patients. Methods: Data from consecutive patients with International Federation of Gynecology and Obstetrics (FIGO) stage IIIC-IV disease, who underwent optimal IDS (<1cm) after NAC, were obtained via a retrospective chart review. Patients were classified into a lymph node sampling (LNS; node count <20) group and an LND (node count ≥20) group. Results: Among 133 study patients, 65 and 68 underwent LND and LNS, respectively, during IDS. Overall survival (OS) was significantly better in the LND group than in the LNS group. In subgroup analysis with negative lymphadenopathy on preoperative imaging, progression-free survival (PFS) and OS were significantly better in the LND group than in the LNS group. Follow-up of subsequent recurrences showed significantly lower nodal and peritoneal recurrence rates among patients who underwent LND. Multivariate analysis identified LND as an independent prognostic factor for PFS and OS. Conclusion: Systematic LND may have therapeutic value in advanced EOC patients treated with NAC and IDS.

UR - http://www.scopus.com/inward/record.url?scp=85026322380&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026322380&partnerID=8YFLogxK

U2 - 10.1002/jso.24669

DO - 10.1002/jso.24669

M3 - Article

VL - 116

SP - 329

EP - 336

JO - Journal of Surgical Oncology

JF - Journal of Surgical Oncology

SN - 0022-4790

IS - 3

ER -